Surgical Innovations Group plc

("Surgical Innovations", the "Company", or the "Group")

Board Changes

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces an evolution to the Board of Directors of the Company as detailed below.

The Company announces the appointments of Roy Davis, Andrew Boteler and Duncan Soukup as Non-Executive Chair, Independent Non-Executive Director and Non-Executive Director respectively, with immediate effect.

Simultaneously, Jonathan Glenn and Keyvan Djamarani will step down from the Board as Non-Executive Chair and Non-Executive Director respectively with immediate effect. Jonathan and Keyvan joined the Board in 2023 and during this time have been instrumental in the driving the operational review of the business.

Roy joins the Board with a mandate to work alongside the current Executive Directors, David Marsh and Brent Greetham to drive value creation for shareholders over the medium term.

Roy Davis

Roy is an experienced executive with over 35 years of global experience in a variety of industries including medtech, diagnostics and technology sectors. He is currently Chairman of Inspiration Healthcare Group plc, a leading neonatal respiratory company, and Foster & Freeman Ltd (the trading name of the Galton group of companies), a leading forensic imaging manufacturer. He is also a Non-Executive Director of Futura Medical plc, a UK pharmaceutical company focussed on the sexual health market and a Senior Advisor to Moore Walker Partners, a Healthcare & Technology Advisory Services company. Roy was previously Chairman of LunglifeAI plc, Medica Group plc until its sale to IK Partners in 2023 and Chairman of Edinburgh Molecular Imaging Ltd and RAIR Health Ltd.

Before these Non-Executive roles Roy served as the Chief Executive Officer of Optos plc, a leading ophthalmology medical device business, from 2008 until June 2016 when he stepped down following the company's acquisition by Nikon Corporation. Before joining Optos, he served from 2007 as Chief Executive Officer of Gyrus Group plc, a leading medical device company, prior to its acquisition by the Olympus Corporation of Japan in 2008, having previously served as Chief Operating Officer of Gyrus from 2003 and a Non-Executive Director since the company's flotation in 1997.

Prior to this, Roy spent almost ten years with Arthur D Little, the global management consulting company, where he was vice president and global head of its operations management business. His early career included experience in the electronics, oil, and automotive sectors. Roy holds a mechanical engineering degree from the University of Southampton and an MBA from the London Business School.

Roy will become Chair of the Nomination Committee and be a member of the Renumeration and Audit Committees, effective immediately.

Andrew Boteler

Andrew brings more than 30 years' experience in both Executive and Non-Executive roles in the financial sector. Andrew is currently Non-Executive Director and Audit Committee Chair at Octopus AIM VCT plc and Non-Executive Director and Audit Committee Chair at Cake Box Holdings plc. Andrew was previously Non-Executive Director and chair of Remuneration and Audit at LungLifeAI plc.  He has been on CEN Group Holdings' Advisory Panel since 2021. Previously, he was CFO at Gooch & Housego PLC (2009-2019) and Finance Director at Riverford Organic Farmers (2019-2023).

Andrew will become Chair of the Audit and Remuneration Committees and a member of the Nominations Committee, effective immediately.

Duncan Soukup

Duncan has over 35 years of investment experience. Having worked in investment banking for 10 years (1984-1994), latterly with Bear Stearns as managing director in charge of the company's non-US equity business, Mr Soukup set up his own investment management business in 1994. Acquisitor plc, a company of which Mr Soukup was a director, was admitted to trading on AIM in January 2000. In 2002, 90 per cent. of the assets of Acquisitor Plc were moved to Acquisitor Holdings Ltd (Bermuda) and Acquisitor Plc was left as an investing company which then acquired Tinopolis Plc, a leading UK independent TV production company. In 2006, Acquisitor Holdings Limited (Bermuda) merged with New York Holdings Ltd. and Baltimore Plc. Shortly thereafter, the combined group was acquired by Oryx International Limited, a Guernsey incorporated investment company. Mr Soukup is currently a Director of a number of UK listed companies including Thalassa Holdings Ltd., Alina Holdings Plc., and Anemoi International Ltd.

Duncan will be a member of the Nominations and Audit Committees, with immediate effect.

Roy Davis, Non-Executive Director, said the following:

"I am delighted to join the Board of Surgical Innovations, a company I have known since my time at Gyrus Group plc. I believe that Surgical Innovation's range of innovative Reposable^TM products provide an exciting platform for improving minimally invasive surgery and I am excited to be able to work with David, Brent and the new Board in looking at how we can maximize shareholder value."

David Marsh, Chief Executive Officer, said the following:

"I am delighted to welcome Roy, Andrew and Duncan to the Board and look forward to working closely with them as the Company takes its next steps. I would also like to take this opportunity to thank Jon and Keyvan for their support and guidance over the past two years, which I have greatly valued and appreciated during our time working together."

For further information please contact:

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company's Reposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.

Further information

Further details of the Group's businesses and products are available on the following websites:

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

To receive regular updates by email, please contact si@walbrookpr.com

The following information is disclosed pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies in relation to Gordon Roy Davis, aged 69.

In addition to the above, Roy Davis was a director of C-Quential Limited until his resignation on 28 February 2001. The company entered into a creditors voluntary liquidation on 11 February 2002 and was subsequently dissolved on 18 August 2007.

The following information is disclosed pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies in relation to Andrew Norman Boteler, aged 59.

The following information is disclosed pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies in relation to Charles Duncan Soukup, aged 71.

Duncan Soukup was appointed as director to Renewable Power & Light Ltd ("RPL") on 18 May 2010 and was a director at the time that RPL was placed into administration on 11 December 2014. Preferential creditors repaid in full and non-preferential creditors distributed a dividend of 0.31 pence in the pound. RPL was dissolved following liquidation on 20 March 2018.

Roy and Andrew do not have an interest in the Company's ordinary shares. Duncan does not hold a direct interest in the Company, but Thalasaa Holdings Ltd is the Company's largest shareholder with an interest of 214,480,101 ordinary shares, representing 22.99% of the total voting rights (as at 12 September 2025).

There are no further disclosures to be made under Schedule Two Paragraph (g) of the AIM Rules for Companies.